Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 63, Issue 4, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01865-18
Keywords
bioavailability; children; dispersible tablets; formulation; levofloxacin; multidrug-resistant tuberculosis; pharmacokinetics
Categories
Funding
- Joint Global Health Trials Scheme of the Department for International Development, UK (DFID)
- Wellcome Trust
- Medical Research Council (MRC UK) [MR/M007340/1]
- South African Medical Research Council (SA MRC) Strategic Health Innovation Partnerships (SHIP) [S003805]
- National Research Foundation of South Africa (NRF) [109056]
- Swedish Foundation for International Cooperation in Research and Higher Education (STINT grant) [SA2015-6259]
- South African National Research Foundation (NRF) [SA2015-6259, 101575]
- MRC [MR/M007340/1] Funding Source: UKRI
Ask authors/readers for more resources
This study characterized the pharmacokinetics of novel 100-mg levofloxacin dispersible tablets in 24 children aged <5 years who had household multidrug-esistant tuberculosus (MDR-TB) exposure. The current data were pooled with previously published data from children (n = 109) with MDR-TB receiving adult (250-mg) levofloxacin tablets, using nonlinear mixed-effects modelling. The adult tablets had 41% lower bioavailability than the novel dispersible tablets, resulting in much higher exposures with the dispersible tablets with the same dose.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
